DEFR14A: BioSig Amends Proxy: Yorkville Debenture Reduced, Streamex Advisor Removed

BioSig Technologies, Inc. filed an amendment to its definitive proxy statement, revising details of its convertible debenture financing with Yorkville and clarifying the absence of a financial advisor for the Streamex acquisition.

Summary

• Amendment No. 1 revises the definitive proxy statement filed on August 4, 2025, for the Special Meeting of Stockholders to be held on September 5, 2025.
• The structure of the secured convertible debenture purchase agreement with YA II PN, Ltd. (Yorkville) has been revised.
• The initial aggregate principal amount of convertible debentures from Yorkville is now $50,000,000, consisting of two $25,000,000 debentures, reduced from the previously stated $100,000,000.
• An additional $50,000,000 in secured convertible debentures may be issued upon mutual agreement of the parties, which can be withheld in either party's sole discretion.
• The purchase price for each convertible debenture remains 96.0% of its principal amount.
• The estimated number of common shares issuable upon conversion of the $50,000,000 debentures at the Floor Price of $1.8828 is 26,556,193 shares, reduced from the previous estimate of 53,112,386 shares for $100,000,000.
• The company clarified that it did not utilize or engage a financial advisor in connection with its consummated acquisition of Streamex Exchange Corporation.
• The description of the effect of abstentions on Proposal 1 (Streamex acquisition approval) was revised, stating they are not counted as votes cast and will not affect the outcome of such proposal.

Sentiment

Score: 4

Explanation: The amendment reveals a reduction in the initially guaranteed capital raise from $100 million to $50 million, with the remaining $50 million now subject to mutual agreement, introducing uncertainty. Additionally, the disclosure that no financial advisor was engaged for the Streamex acquisition could be perceived negatively regarding due diligence and valuation. While capital is still being raised, the terms are less favorable than initially presented.

Positives

• The initial guaranteed capital raise from Yorkville is $50,000,000, providing funds for general corporate purposes, including research and development for PURE EP and Viral Clear, and development of Streamex's gold tokenization platform.
• The potential for an additional $50,000,000 in debenture financing exists, subject to mutual agreement.
• The estimated dilutive effect at the Floor Price is reduced due to the lower initial principal amount of the debentures.

Negatives

• The guaranteed capital from Yorkville has been reduced from $100,000,000 to $50,000,000, with the remaining $50,000,000 contingent on mutual agreement, introducing uncertainty.
• The company did not engage a financial advisor for the Streamex acquisition, which could raise questions about independent valuation or due diligence for a significant transaction.
• Stockholders will incur dilution of their percentage ownership upon conversion of the convertible debentures, which may be substantial and material.

Risks

• Inability to predict the price of common stock at any future date or the timing of Yorkville's conversion decisions.
• The number of shares required upon conversion cannot be predicted, and conversion prices could fall below the Nasdaq Minimum Price.
• Failure to approve Proposal 2 (Yorkville debenture issuance) will prevent the company from issuing the $50,000,000 in convertible debentures.
• If stockholder approval for Proposal 2 is not received, the company may be required to use cash to fulfill obligations to Yorkville, which could impede growth and harm the business if capital is unavailable.
• The company cannot guarantee securing capital if required to use cash for Yorkville obligations.

Future Outlook

The company intends to use the capital from the convertible debentures for general corporate purposes, including funding research and development for PURE EP and Viral Clear, developing Streamex's gold tokenization platform, and for general working capital. The ability to secure the full $100 million from Yorkville is now contingent on mutual agreement for the second $50 million tranche.

Management Comments

• Our Board has determined that the Debenture Purchase Agreement and Convertible Debentures, and our ability to issue the shares of Common Stock upon conversion of the Convertible Debentures in excess of the Debenture Exchange Cap at prices that may be less than the Minimum Price are in the best interests of the Company and our stockholders.
• We cannot predict the price of our Common Stock at any future date, nor do we have any control over the timing of Yorkville's decisions as to when and if to convert its Convertible Debentures.
• Based on current trading prices of our Common Stock, we do not expect that we will be required to issue Conversion Shares at the Floor Price, but it is possible that Yorkville's conversion of the Convertible Debentures from time to time could require us to issue an aggregate number of shares of Common Stock that is substantially more than 20% of our outstanding shares as of July 7, 2025, and the conversion prices could fall below the Minimum Price, depending on the trading price of our Common Stock at the time of conversion.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders will experience dilution from the conversion of debentures, which could be substantial. Their approval is required for key proposals, including the issuance of shares for the Streamex acquisition and the Yorkville debentures. The reduction in guaranteed capital and the lack of a financial advisor for the Streamex acquisition could impact shareholder confidence and valuation.
• Creditors (Yorkville): The terms of their investment have been adjusted, with the second tranche of $50 million now subject to mutual agreement.
• Employees: The capital raised is intended to fund R&D and general working capital, which could support ongoing operations and future projects.

Next Steps

• Stockholders will vote on Proposal 1 (Streamex acquisition share issuance) and Proposal 2 (Yorkville debenture share issuance) at the Special Meeting on September 5, 2025.
• If Proposal 2 is approved, the company will be able to sell the initial $50,000,000 in convertible debentures to Yorkville.
• The company may pursue the additional $50,000,000 in debentures from Yorkville upon mutual agreement.

Key Dates

Recommendation

The filing is an amendment clarifying details rather than announcing new operational results. While the guaranteed capital raise from Yorkville was reduced from $100 million to $50 million, the potential for an additional $50 million remains. The disclosure about not using a financial advisor for the Streamex acquisition is a notable point that could be viewed negatively. Given these mixed signals and the nature of an amendment, a 'hold' recommendation is appropriate as investors should await further developments or the outcome of the Special Meeting before making significant changes to their position. The long-term implications of the revised financing and acquisition details need further assessment.

Keywords

BioSig Technologies, SEC filing, DEFR14A, Proxy Statement, Convertible Debentures, Yorkville, YA II PN, Streamex Exchange Corporation, Acquisition, Capital Raise, Stockholder Meeting, Dilution, Corporate Governance, PURE EP, Viral Clear, Gold Tokenization